Flying The Web For News.
  • Epiphany
    Epiphany
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

Details
Category: Globe NewsWire News Distribution Service

Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the preprint publication of a  study demonstrating effective treatment of abdominal aortic aneurysm (AAA) in an animal model.1 The study was conducted…


Posted: 2024-07-19 13:01:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | altamira | therapeutics | announces


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles - Newscast

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Tue, 31 Dec 2024 14:00:00 GMT linear mRNA Filed provisional patent application, further expanding IP portfolio Altamira Therapeutics Ltd. (“Altamira ... vehicles that fit their specific needs.” This press release may contain ...

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Tue, 31 Dec 2024 01:00:00 GMT Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery Circular mRNA significantly increasing protein expression vs. linear mRNA Filed provisional patent application, ...

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

Fri, 20 Dec 2024 13:00:00 GMT Altamira Therapeutics Ltd. (“Altamira” or the “Company ... there is no requirement to perform any reverse stock split.” This press release contains “forward-looking statements” within the meaning of ...

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

Fri, 20 Dec 2024 00:00:00 GMT Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today ...

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

Thu, 19 Dec 2024 16:00:00 GMT Altamira Therapeutics Ltd. (“Altamira&CloseCurlyDoubleQuote ... CloseCurlyDoubleQuote; This press release contains “forward-looking statements” within the meaning of the Private ...


Blow Us A Whistle